7/25/2019 Chronic Hepatitis B 1

1/1

Chronic hepatitisB

1. HBsAg+ve for > 6 months

2. Serum HBV DNA: HBeAg+ve: >20,000 I!m" , HBeAg#ve: 2,000#20,000 I!m"

$. %ers&stent or &nterm&ttent e'ev(t&on &n A") 'eve's

*. "&ver &os-: &'/!o/er(te!severe nero&nf'(mm(t&on

Inactive carrier state1. HBsAg+ve for >6 months

2. HBeAg#ve (n/ (ntHBe +ve

$. Serum HBV DNA 2,000 I!m"

*. %ers&stent'- norm(' A") 'eve's

. "&ver &os-: Asene of s&gn&f&(nt &nf'(mm(t&on

Resolved hepatitis B 1. %rev&ous 3no4n h&stor- of (ute or hron& He B or the

resene of (ntHB 5 (ntHBs

2. HBsAg#ve

$. n/etet('e serum HBV DNA

*. Norm(' A") 'eve's *0 I!m' for In/&(ns7

)he re/om&n(nt route of tr(nsm&ss&on &shor&8ont(' (n/ the most ommon'- ourr&ng

genot-es (re A (n/ D.

A. Management of CHB

Counseling and Prevention ofTransmission

9 / u ( t & n g ( t & e n t s ( n / sre(/&ng (4(reness (out HBV &nfet&on &s ru&(' for

suessfu' (nt&v&r(' ther(- (n/ (n ur the sre(/ of th&s &nfet&on.

ounse'&ng of (t&ents on revent&onof tr(nsm&ss&on of HBV, (/v&e on '&fest-'e (t&v&t-, /&et,

('oho' use,

et.7 (n/ other re/&sos&ng f(tors (s 4e'' (s v(&n(t&on of h&gh r&s3 (t&ents seu(' (n/

househo'/ memers &n 'ose ont(t 4&th (t&ents! (rr&ers, HBsAg os&t&ve mothers,

he('th(re 4or3ers, /&('-s&s (t&ents, &n(rer(te/

(t&ents, et.7. A//&t&on(''-, use of he(t&t&s B &mmune g'ou'&n HBI;7 &s (/vo(te/ for

&nf(nts orn to &nfete/ mothers ('ong 4&th he(t&t&s B v(&ne (t /e'&ver- fo''o4e/ -

om'ete v(&n(t&on ser&es7 9erts &n In/&( suggest (t 'e(st t4o sess&ons of ounse'&ng, one

(t &n&t&(' v&s&t (n/ the other (fter &nvest&g(t&ons 4&th fous on

(''ev&(t&ng un/ue (n&et- of the (t&ent. )he m(&n /&suss&on o&nts &n'u/e st(ge of the

/&se(se (n/ &ts rognos&s, revent&on of /&se(se tr(nsm&ss&on, (v(&'('e tre(tment ot&ons,

the&r s&/e effets (n/ the &mort(ne of om'&(ne to

ther(-.

Initial Evaluation